Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 7/7/15  and contains information from public web pages and contributions from the ZoomInfo community.

Dr. John Didsbury

Wrong Dr. John Didsbury?

Founder and Chief Executive Offic...

Phone: (919) ***-****  
Email: d***@***.com
T3D Therapeutics Inc
68 T.W. Alexander Drive
Research Triangle Park , North Carolina 27709
United States

Company Description: T3D Therapeutics Inc. is a privately-held Research Triangle Park, NC-based company incorporated in 2013. The company is committed to developing disease remedial...   more
Background

Employment History

Board Memberships and Affiliations

Education

  • Ph.D.
  • PhD
  • Ph.D. , Medical Microbiology
    University of Vermont Medical College
  • Bachelor of Arts , biology/chemistry
    University of Connecticut
91 Total References
Web References
Press Releases :: DARA BioSciences, Inc. (DARA)
ir.darabio.com, 18 June 2013 [cached]
he T3D Therapeutics team, including John Didsbury, who was Chief Scientific Officer of DARA from 2005 to 2009, is comprised of leading experts in the field of PPAR science and are extremely familiar with the compound. e believe they will apply the necessary resources to explore DB959 in multiple, potential high-value indications.Importantly, the agreement affords DARA upfront considerations as well as future potential revenue based on progression of the DB959 developmental program."
DARA previously reported that it was actively seeking to out-license DB959 as part of its strategic plan to focus on the commercialization of oncology supportive care products.
John Didsbury, Ph.D., Founder and Chief Executive Officer of T3D Therapeutics, commented, "The T3D Therapeutics team has a long history with DB959, and we plan to develop it as a transformational new therapy for the treatment of Alzheimer's disease.Unlike other therapies in development that target a single pathology, typically the reduction or prevention of beta amyloid plaque buildup, T3D expects DB959 will afford a multidimensional opportunity, with the potential to improve several Alzheimer's disease pathologies including addressing beta amyloid plaque issues.Positive improvements in disease pathologies such as neuro-inflammation, neuronal cell loss, neurotransmitter deficits, tau neurofibrillary tangles, and insulin resistance / lowered cerebral glucose metabolism also are anticipated."
Didsbury continued, "With today's highly competitive diabetes and dyslipidemia market, we believe that DB959 will be better positioned to address unmet medical needs for new central nervous system (CNS) therapies.Given the neuroprotectant potential of DB959's mechanism of action and the growing evidence of metabolic disorders contributing to CNS diseases, we are excited to commence an aggressive development program for DB959."
...
John Didsbury, Ph.D. T3D Therapeutics CEO 919-949-0517
medicaldevicelicensing.com: Industry news
medicaldevicelicensing.com, 18 Feb 2013 [cached]
RALEIGH, North Carolina, March 25 /PRNewswire/ -- DARA BioSciences(TM) (Nasdaq: DARA) announced today the appointment of John Didsbury, Ph.D. as President and Chief Operating Officer. Dr.... http://medicaldevicelicensing.com/redirs/news_rss/news/viewNewsML/611 http://medicaldevicelicensing.com/redirs/news_rss/news/viewNewsML/611
...
www.sec.gov, 11 Sept 2008 [cached]
0001424590 Didsbury John C/O DARA BIOSCIENCES, INC. 4505 FALLS OF NEUSE ROAD SUITE 125 RALEIGH NC 27609 0 1 0 0 COO and Chief Scientic Officer
John Didsbury, Ph.D. (View ...
www.ddcoi.org, 19 April 2011 [cached]
John Didsbury, Ph.D. (View Profile) President and CEO, DDCOI
PR Newswire: DARA BioSciences, Inc. Announces New Officer And Director Appointments
pharmalicensing.com [cached]
RALEIGH, North Carolina, March 25 /PRNewswire/ -- DARA BioSciences(TM) (Nasdaq: DARA) announced today the appointment of John Didsbury, Ph.D. as President and Chief Operating Officer. Dr. Didsbury has served as DARA's Chief Scientific Officer since November 2006. Dr. Didsbury previously served as President and CEO of Nuada Pharmaceuticals, Inc. Dr. Didsbury replaces Richard A. Franco, who notified the Board of Directors on March 21, 2008 of his decision to resign.
...
John has a deep understanding of the science behind the drugs in DARA's pipeline in addition to experience running a company.
...
Dr. Didsbury commented, "It is a privilege to assume the role of DARA's President.
Other People with the name "Didsbury":
Other ZoomInfo Searches
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.